Director dealings: 4D Pharma board up stakes
By Iain Gilbert
Date: Wednesday 22 May 2019
(Sharecast News) - 4D Pharma revealed that chief executive Duncan Peyton had acquired 101,199 ordinary shares in the AIM-listed drugmaker on Wednesday.
Peyton, who co-founded equity investment vehicle Aquarius back in 2005, purchased the shares on Tuesday at an average price of 99.40p each, for a total value of £100,592.
Chief scientific officer Alex Stevenson also snapped up some shares on the same day - spending £49,978 on 50,998 ordinary shares at 98p each.
4D Pharma shares dropped on Tuesday after the group warned investors that it would have to tap the market for more money within the next few months.
As of 1635 BST, 4D shares had slipped 2.29% to 98.20p.
Top Director Buys
4D Pharma (DDDD)
Director name: Mr Duncan Joseph Peyton
Amount purchased: 101,199 @ 99.40p
Value: £100,592
Phoenix Global Resources (PGR)
Director name: Mr Sir Michael Rake
Amount purchased: 300,000 @ 22.00p
Value: £66,000
4D Pharma (DDDD)
Director name: Mr Alexander James Stevenson
Amount purchased: 50,998 @ 98.00p
Value: £49,978
JPMorgan Multi-Asset Trust (MATE)
Director name: Sir Laurence Magnus
Amount purchased: 50,000 @ 92.38p
Value: £46,190
SDX Energy Inc. (DI) (SDX)
Director name: Mr Mark Reid
Amount purchased: 84,185 @ 23.76p
Value: £20,002
Top Director Sells
British American Tobacco (BATS)
Director name: Mr Jack Bowles
Amount sold: 6,811 @ 2,947.00p
Value: £200,720
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN